Healthcare · Health Information Services · NASDAQ · United States
$5.25+0.00%
Market cap $871MNext earnings 2026-10-29Updated Oct 20, 2026
Our verdict
Trades 59% above our fair value
Price
$5.25
Model fair valueConfidence: medium
$3.29
Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionTalkspace Inc. Common Stock (TALK)
Fair value (3 models)
Not available
ACCE price target
$4.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Price used: $5.25 at the close on 26 Aug 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
52
out of 100
Analysts
86% buy
7 covering
P/E
0.0x
forward 43.3x
1-year return
+96.6%
Dividend yield
0.00%
Talkspace Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Talkspace runs a virtual behavioral health platform that connects members with licensed therapists and psychiatrists, and it sells its services to employers, health plans and government payers as well as to individuals. The core case rests on a network that gets paid through those channels, with revenue growing 13.6% and gross margin at 38.6%, a level that leaves room to scale if operating costs keep flattening. The investment question is whether that growth converts into profit: operating margin is still negative at -2.0%, and the stock trades at a forward P/E of 43.3 on a roughly $871M market cap, so the multiple already assumes a turn that has not yet shown up in the numbers. The stock carries a score of 52/100 and sits outside the major indices, so it is not being bought for index flows. It merits a deeper look mainly to test how quickly margins can move from negative to positive and whether payer contract wins keep the top line compounding.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Earnings miss and margin pressure
Q3 2026 EPS missed by 133.3%, operating margin is -2.0% and free cash flow is $-2,107,000. Earnings growth of +181.1% rests on a low base, not on operating strength.
moderate
Price above ACCE target
Shares at $5.25 trade 16.7% above the ACCE price target of $4.50. The ACCE score also fell from 59 to 52 over 90 days.
moderate
Revenue growth slowing
Revenue grew 13.6% year on year, against a 24.6% five-year CAGR, and fell 2.1% quarter on quarter.
AI research notes
AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-06-30 · prices to Aug 26, 2026
Why it could do well
Revenue grew 13.6% over the past year, and the five-year average annual growth rate is 24.6%.
Six of seven analysts rate the stock Buy or Strong Buy, and their mean price target sits 21.4% above the current share price.
The diluted share count fell 1.6% last fiscal year, so each remaining share holds a slightly larger claim on the business.
Why it could disappoint
Free cash flow over the last twelve months was negative at -$2M, so the business is still consuming cash.
The forward P/E of 43.3x is well above the sector median of 24.1x, leaving little room for disappointment.
The latest earnings per share came in at -0.01 against 0.03 expected, a miss of -133.3%, and the net margin is only 0.1%.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where TALK's valuation models land
Price
$5.25
Model fair valueConfidence: medium
$3.29
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores